Fluid p-tau species are tightly associated with cerebral amyloidosis assessed by CSF or PET biomarkers during preclinical AD, starting to increase when only subtle abnormalities in CSF Aβ42/40 are detectable [20, 45]. Here, MAPT is linked to Alzheimer disease.